Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 14fludarabine 8Rituximab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Vincristine 4Doxorubicin 4Dexamethasone 4zanubrutinib 3Prednisone 3Nivolumab 3Etoposide 3tazemetostat 2tafasitamab 2pirtobrutinib 2pembrolizumab 2glofitamab 2etoposide phosphate 2cemiplimab 2acalabrutinib 2Leukapheresis 2Immunotherapy, Adoptive 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cisplatin 2Cell- and Tissue-Based Therapy 2Biopsy 2venetoclax 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × tafasitamab × 30 days × Clear all
NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡